MedTrace Logo

A Comparative Study of New Medications for Psychosis in Adolescents

NCT00222495 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2006-09-11

No results posted yet for this study

Summary

The overall goal of this study is to determine the efficacy and tolerability of three atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in the treatment of adolescents with psychosis. It is hypothesized that the three medications will be equally effective in reducing the symptoms of psychosis.

Conditions

  • Psychotic Disorders
  • Schizophrenia
  • Schizophreniform Disorders
  • Schizoaffective Disorders

Interventions

DRUG

quetiapine

DRUG

olanzapine

DRUG

risperidone

Sponsors & Collaborators

Principal Investigators

  • Jonathan Jensen, M.D. · University of Minnesota

  • S. Charles Schulz, M.D. · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Completion
2006-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00222495 on ClinicalTrials.gov